Anebulo Pharmaceuticals Files 8-K
Ticker: ANEB · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Anebulo Pharma filed an 8-K on 4/14 for events on 4/11, including corporate docs & financials.
AI Summary
Anebulo Pharmaceuticals, Inc. filed an 8-K on April 14, 2025, reporting events as of April 11, 2025. The filing includes amendments to its Articles of Incorporation or Bylaws and financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on June 30.
Why It Matters
This 8-K filing indicates corporate actions and financial reporting updates for Anebulo Pharmaceuticals, Inc., which could impact investors' understanding of the company's structure and financial status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 001-40388 (filing_id) — Commission File Number
- 85-1170950 (tax_id) — IRS Employer Identification No.
- April 11, 2025 (date) — Date of earliest event reported
- April 14, 2025 (date) — Date of report
FAQ
What specific amendments were made to Anebulo Pharmaceuticals, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What financial statements and exhibits are included in this 8-K filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the provided text.
When is Anebulo Pharmaceuticals, Inc.'s fiscal year end?
Anebulo Pharmaceuticals, Inc.'s fiscal year end is June 30.
What is the principal executive office address for Anebulo Pharmaceuticals, Inc.?
The principal executive office address is 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
What is the Commission File Number for Anebulo Pharmaceuticals, Inc.?
The Commission File Number for Anebulo Pharmaceuticals, Inc. is 001-40388.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Anebulo Pharmaceuticals, Inc. (ANEB).